ALXN Alexion Pharmaceuticals Inc.

140.24
-2.92  -2%
Previous Close 143.16
Open 143.40
Price To book 3.53
Market Cap 31299498759
Shares 223,185,245
Volume 1,351,511
Short Ratio 3.24
Av. Daily Volume 1,442,985

SEC filingsSee all SEC filings

  1. 8-K - Current report 171088740
  2. 8-K - Current report 171080087
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17986371
  4. 8-K - Current report 17984707
  5. 8-K - Current report 17909558

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrollment to be completed in 2017 with data due 2018.
Eculizumab
Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)
Phase 3 enrollment to be completed early 2018; expects to initiate a Phase 3 trial in pediatric patients 3Q 2017.
ALXN1210
atypical Hemolytic Uremic Syndrome (aHUS)
Phase 2/3 enrolling.
ALXN1101
Molybdenum cofactor deficiency (MoCD) Type A
Phase 3 data due 2Q 2018.
ALXN1210
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 1/2 ongoing. No additional studies planned.
SBC-103
MPS IIIB
(sBLA) PDUFA date October 23, 2017.
Eculizumab
Refractory generalized myasthenia gravis (gMG)

Latest News

  1. See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
  2. With An ROE Of 6.11%, Has Alexion Pharmaceuticals Inc’s (ALXN) Management Done A Good Job?
  3. ALEXION INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alexion Pharmaceuticals, Inc. – (ALXN)
  4. Is It Too Late To Buy Facebook?
  5. Alexion Pharmaceuticals Trying To Close In On Key Technical Measure
  6. Alexion to Report Third Quarter 2017 Results on Thursday, October 26, 2017
  7. ALEXION INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alexion Pharmaceuticals, Inc. - (ALXN)
  8. How Strensiq Could Boost Alexion’s Long-Term Growth
  9. Gauging Alexion’s 2018 Growth with Soliris
  10. How Is Alexion Pharmaceuticals Positioned after 1H17?
  11. Alexion on the Street: Analyst Recommendations in October
  12. The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO
  13. Alexion Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ALXN) : October 2, 2017
  14. 3 Biotech and Pharma Stocks with Key FDA Catalysts this October
  15. Roivant Makes $116 Million Investment In Arbutus, Backing Battle With Moderna
  16. When Should You Sell Alexion Pharmaceuticals Inc (ALXN)?
  17. Alexion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALXN-US : September 29, 2017